MyGene2 holds cases from 1,225 families, submitted by 880 user accounts, which include 723 unique genes, among them many new disease genes.
A growing number of companies are offering canine DNA tests for breed identification, genetic disease mutations, and traits.
Despite years of experience of returning genetic test results, clinicians and researchers are still faced with many questions, such as what to do about VUS and secondary findings.
Last week, the company launched whole-genome sequencing of children for customers of its ViaCord cord blood and tissue banking business.
The company plans to use proceeds to further invest in its development of molecular testing and other strategies in the preventive medicine space.
Over the next month the company plans to expand its preconception screening test, which it launched widely earlier this year, by adding about 90 X-linked disorders.
With the new certification in hand, the company plans to expand its business in the US through its Pennsylvania-based subsidiary, B. Braun CeGaT.
Last year, GenePeeks raised $16 million in a Series B funding round from 5AM Ventures, Columbus Nova Technology Partners, Alexandria Venture Investments, Alta Partners, and others.
Precision medicine platform developer 2bPrecise, a subsidiary of Allscripts, will develop and test genomics care protocols with Mayo Clinic.
At the European Society of Human Genetics annual meeting in Copenhagen this week, several groups presented studies involving automated facial analysis software.
Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.
The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.
CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.
In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.